Drug Profile
Research programme: adenosine A2A receptor agonists - GlaxoSmithKline
Latest Information Update: 21 Jan 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Adenosine A2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 18 Aug 2000 Preclinical development for Inflammation in United Kingdom (unspecified route)